Comparing the current results to its competitors, Prf Technologies Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Prf Technologies Ltd 's competitors' average revenue growth of 112.52 %, achieved in the same quarter.
November 20, 2024
PainReform Reveals Promising Topline Data for PRF-110 in Phase 3 Clinical Trial Tel Aviv, Israel PainReform Ltd. (Nasdaq: PRFX), a clinical-stage pharmaceutical company focused on the reformulation of established therapeutics, has recently announced the receipt of preliminary topline data from the Phase 3 clinical trial assessing PRF-110 for post-surgical pain management in patients undergoing bunionectomy. This announcement comes amidst challenging financial circumstances for the company, with a notable decline in revenues compared to its competitors.The clinical trial, conducted in collaboration with Lotus Clinical Research, aims to evaluate the efficacy and safety of PRF-110 in managing pain following...
September 11, 2024
Navigating Post-Surgical Pain Management Post-surgical pain management is a critical component of patient care, directly influencing recovery and overall outcomes. PainReform Ltd. a clinical-stage specialty pharmaceutical company based in Tel Aviv, Israel, is making significant strides in this area with its proprietary formulation, PRF-110. This formulation aims to provide an effective solution for managing pain following surgical procedures, particularly bunionectomies. Recently, PainReform has announced positive compatibility results and safety profiles for PRF-110 in human clinical trials, bolstering the formulation s potential in enhancing patient recovery experiences. Compatibility and Safety Assurance...
August 21, 2024
: The PainReform Bunionectomy Study offers significant insights into the management of post-operative pain through a novel delivery method of PRF-110. This article reviews the study findings, comparing traditional pain management approaches with the innovative PRF-110 delivery system, and discusses the implications for future bunionectomy procedures.Bunionectomy, a common surgical procedure for correcting hallux valgus, often results in post-operative pain that can impede recovery and patient satisfaction. Traditionally, pain management has relied on systemic opioids and analgesics, which can carry risks of side effects and dependency. To address these challenges, the PainReform Bunionectomy Study focused on...
April 2, 2024
In the realm of modern medicine, the ever-elusive quest for effective pain management techniques has long been a topic of intense research and development. However, PainReform, a pioneering pharmaceutical company, may be on the brink of a revolutionary breakthrough in this field. With their ground-breaking drug candidate, PRF-110, PainReform recently achieved a significant milestone, enrolling 50% of eligible participants in the second part of its phase 3 clinical trial for bunionectomy pain management. Moreover, the company is confidently on track to announce top-line data from this trial by mid-2024, signaling a potential game-changer in the field of pain management.PainReform s PRF-110, a synthetic peptid...
January 3, 2024
In a groundbreaking development in the field of postoperative pain management, PainReform has recently unveiled the astounding results of their head-to-head comparison between PRF-110 and the current market-leading post-surgical analgesia. The findings not only demonstrate PRF-110 s superior formulation properties but also showcase its exceptional capability of extended postoperative pain relief.Postoperative pain management has long been a significant concern for both patients and healthcare professionals. The ability to provide effective pain relief while minimizing potential side effects is crucial in improving overall patient outcomes and optimizing recovery. Recognizing this pressing need, PainReform em...
Elite Pharmaceuticals Inc. is a pharmaceutical company that specializes in developing and manufacturing generic and abuse-deterrent controlled-release products. Their business model focuses on conducting research, obtaining regulatory approvals, and licensing their products to other pharmaceutical companies for commercialization and distribution.
Nutriband Inc operates through a business model focused on developing and commercializing innovative transdermal topicals and supplement products, utilizing their patented Nutrient Delivery System to enhance the absorption and effectiveness of nutraceutical and pharmaceutical ingredients.
Sources:
Prf Technologies Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prf Technologies Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
